Tirzepatide CAS: 2023788-19-2 China factory whatsap:+8613014333516

Obesity is a chronic disease that requires long-term treatment and is associated with many serious health consequences and reduced life expectancy. Obesity-related complications are numerous, including type 2 diabetes, heart disease, obstructive sleep apnea, chronic kidney disease, nonalcoholic fatty liver disease, and cancer.

Novo Nordisk is currently investigating semaglutide 2.4mg subcutaneously injected once a week as a treatment for adult obesity. semaglutide is a GLP-1 hormone analogue that induces weight loss by reducing hunger and increasing satiety, thereby helping people eat less and consume fewer calories.